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Background: A previous analysis of the placebo arm of the Prostate Cancer Prevention 
Trial (PCPT) reported 82% overall prevalence of intraprostatic inflammation and identified 
a link between inflammation and higher-grade prostate cancer and serum PSA. Here we 
studied these associations in the PCPT finasteride arm.  
Methods: Prostate cancer cases (N=197) detected either on a clinically indicated biopsy 
or on protocol-directed end-of-study biopsy, and frequency-matched controls (N=248) with 
no cancer on an end-of-study biopsy were sampled from the finasteride arm. Inflammation 
in benign prostate tissue was visually assessed using digital images of H&E stained 
sections. Logistic regression was used for statistical analysis. 
Results: In the finasteride arm, 91.6% of prostate cancer cases and 92.4% of controls had 
at least one biopsy core with inflammation in benign areas; p < 0.001 for difference 
compared to placebo arm. Overall, the odds of prostate cancer did not differ by prevalence 
(OR=0.90, 95% CI 0.44-1.84) or extent (P-trend=0.68) of inflammation. Inflammation was 
not associated with higher-grade disease (prevalence: OR=1.07, 95% CI 0.43-2.69). 
Furthermore, mean PSA concentration did not differ by the prevalence or extent of 
inflammationin either cases or controls.  
Conclusion: The prevalence of intraprostatic inflammation was higher in the finasteride 
than placebo arm of the PCPT, with no association with higher-grade prostate cancer. 
Impact: Finasteride may attenuate the association between inflammation and higher-
grade prostate cancer. Moreover, the missing link between intraprostatic inflammation and 




A recent analysis in the placebo arm of the Prostate Cancer Prevention Trial 
(PCPT) indicated a greater prevalence and extent of intraprostatic inflammation in benign 
prostate tissue of higher-grade prostate cancer cases than controls (1). The PCPT was a 
placebo-controlled, randomized clinical trial studying whether finasteride, a drug that 
inhibits the conversion of testosterone into the more potent androgen dihydrotestosterone 
in the prostate, could decrease the risk of prostate cancer in men initially at low to 
moderate risk of the disease. Finasteride has been reported to reduce symptoms of type 
IIIa chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) (2), a condition associated 
with intraprostatic inflammation, and possibly also those of bacterial prostatitis (3). 
However, it is currently unknown how finasteride affects the prevalence and extent of 
intraprostatic inflammation and whether it affects the association between inflammation 
and prostate cancer risk, including higher-grade disease. 
We had 3 a priori hypotheses concerning finasteride’s effect on intraprostatic 
inflammation: 1) less inflammation because of a possible reduction of CP/CPPS symptoms 
during finasteride treatment (2), 2) absolute increase in inflammation in response to 
finasteride-mediated epithelial cell death and prostate shrinkage (4), or 3) proportional 
increase in inflammation based on the prostate volume reduction causing the same 
number of immune cells to cover a larger portion of the remaining prostate tissue. 
Thus, we performed a case-control study nested in the finasteride arm of the PCPT 
to evaluate the association between intraprostatic inflammation and prostate cancer risk 
during finasteride treatment. A unique feature of PCPT was that all men underwent annual 
prostate-specific antigen (PSA) screening and digital-rectal examination (DRE), and men 
not diagnosed with prostate cancer by the end of the 7-year follow-up period were asked 
to undergo an end-of-study prostate biopsy irrespective of whether they had a clinical 
indication, that is, suspicion of prostate cancer (5). Consequently, tissue was available 
from both prostate cancer cases and from cancer-free controls. 
 
Materials and Methods 
Study population and design 
We studied a subset of men who participated in the multisite PCPT (5). The trial 
included men who were ≥55 years; had no abnormalities detected on DRE and had PSA 
value ≤3 ng/mL and no to moderate lower urinary tract symptoms (American Urological 
Association Symptom Index <20) at baseline. A total of 18,882 men were enrolled in the 
trial between 1993 and 1997 and were randomized to receive finasteride (5 mg/day) or 
placebo for 7 years. At trial entry, participant weight and height were measured for 
calculation of body mass index (BMI; kg/m2). Additionally, participants completed a 
questionnaire, which included questions on demographics, lifestyle, and medical factors, 
such as cigarette smoking history, first-degree family history of prostate cancer, and 
history of diabetes.  
During follow-up, participants were screened annually for prostate cancer by PSA 
and DRE. The PSA threshold for prostate biopsy was 4 ng/mL. To ensure equal 
percentage of prostate biopsies in both study arms, the measured PSA values were 
initially doubled for finasteride-treated men, and from the beginning of the fourth year in 
the study a multiplying factor of 2.3 was used. If either PSA or DRE was abnormal, men 
were recommended for prostate biopsy. Cancers detected on a biopsy done for clinical 
suspicion of prostate cancer were termed “for-cause" biopsy detected cases. To catch 
cancer cases missed because of finasteride’s PSA lowering effect, all men in both arms of 
the trial who were not diagnosed with prostate cancer during the trial were requested to 
undergo prostate biopsy after seven years on the trial irrespective of their PSA 
concentration or DRE status (5). Cancers detected on these biopsies were considered to 
be for-cause biopsy detected if the man had an elevated PSA or abnormal DRE, 
otherwise, these cancers were considered to be end-of-study biopsy detected.  
Pathologic evaluation of the prostate biopsy cores, including evaluation of Gleason 
sum, was confirmed at the Prostate Diagnostic Laboratory at the University of Colorado; 
pathologists were blinded to the trial arm and exposure information (5).  
Adherence (whether the participant was on or off finasteride) and compliance to 
finasteride (the proportion of doses used) were checked biannually at research visits for 
reissuing of medication and counting of remaining finasteride doses (5). 
The PCPT was approved by the institutional review boards at each trial site. This 
study on inflammation was approved by the Johns Hopkins Bloomberg School of Public 
Health Institutional Review Board and by the Colorado Multiple Institutional Review Board. 
 
Prostate cancer cases and controls 
To create a case-control study for evaluation of intraprostatic inflammation we used 
a sub-sample of a previously developed case-control study nested in the PCPT that 
included all 1,809 eligible men diagnosed with prostate cancer (cases) either on for-cause 
or end-of-study biopsy, and a sample of 1,809 men who were negative for prostate cancer 
on end-of-study biopsy (controls) (6). To enrich the population for non-white men, all 372 
non-white men were included in the control group, and 1,437 men were sampled from the 
white men without prostate cancer to achieve the target of 1,809 controls. Controls were 
frequency matched to cases on age at baseline, first-degree family history of prostate 
cancer at baseline, and treatment arm.  
For the inflammation study 197 cases from the finasteride arm of the PCPT were 
selected from the larger case-control population. To enhance statistical efficiency, we 
sampled approximately equal numbers of cases by grade (Gleason sum ≤6; or 7-10) and 
biopsy indication (for-cause, end-of-study). Additionally, 248 controls who did not have 
cancer at end-of-study biopsy were sampled from the finasteride arm. 
 
Assessment of inflammation in benign prostate tissue from biopsies 
  The H&E stained slides of the prostate biopsies used for prostate cancer diagnosis 
during the PCPT were reviewed for inflammation. For each man, 6-10 needle biopsy cores 
were usually taken. Multiple cores were mounted on each slide. We sampled a median of 
2 slides per man, yielding, on average, 3.3 biopsy cores per man. Cores were mainly from 
the apex or mid-gland.  
In both cases and controls, we evaluated inflammation in only the benign areas of 
the biopsy cores. To blind the pathologist to case-control status, all areas of 
adenocarcinoma (cases) and arbitrary benign areas on cores without cancer (cases and 
controls) were masked with ink on the slide cover slips (1). We used the Aperio 
ScanScope slide scanner (Aperio, Vista, CA) to digitally image the H&E stained slides. 
Slide images were uploaded into the Spectrum Digital Pathology Information Management 
System (Aperio, Vista, CA) and were visually reviewed for inflammation online using the 
Aperio ImageScope Viewer Software package.  
Assessment of inflammation in benign tissue in the PCPT has been described in 
detail previously (1). In short, the following aspects were evaluated: 1) the presence of any 
inflammatory cells, any acute inflammatory cells (e.g., polymorphonuclear cells), and any 
chronic inflammatory cells (e.g., cells with an appearance consistent with that of 
lymphocytes and macrophages) in the benign tissue for each biopsy core on each slide; 2) 
the proportion of the total benign (unmasked) biopsy core area per slide that had 
involvement of any inflammatory cells, either acute inflammatory cells, or chronic 
inflammatory cells; and 3) an inflammation score using a modified version of the 
histopathological classification system developed by Nickel et al. (7). For the latter, the 
extent (1=focal, 2=multifocal, 3=diffuse) and grade (1=mild, 2=moderate, 3=severe) of 
inflammation present was recorded separately for the luminal, intraepithelial, and stromal 
compartments of the benign prostate tissue on each slide. All of the images for this study 
were reviewed by a single pathologist (BG), who was trained to score inflammation using 
these methods.  
 
Statistical analysis 
We used linear regression with model adjustment for baseline age, family history of 
prostate cancer, and race to calculate adjusted means and proportions for population 
characteristics, measures of inflammation, serum PSA, and adherence and compliance to 
finasteride use. Logistic regression with the same model adjustments was used to 
evaluate statistical significance of the differences between cases and controls.  
We used logistic regression to estimate odds ratios (OR) and 95% confidence 
intervals (CI) of prostate cancer overall, and separately for higher-grade (Gleason 7-10) 
and lower-grade (Gleason 6 or less) prostate cancer by inflammation prevalence (i.e., at 
least one biopsy core with inflammation) and extent (i.e., none, some, or all cores with 
inflammation). We adjusted for age, family history of prostate cancer, and race. We 
performed separate analyses for all men (intention-to-treat analysis) and for men on 
finasteride at the time of biopsy to evaluate the biological effect. In further sensitivity 
analyses we evaluated the influence of PSA concentration, Gleason sum and compliance 
to finasteride (≤75% vs. >75% of the assigned finasteride doses used) on these 
associations.  
Logistic regression was performed using IBM SPSS statistics 20 statistical software 
(Chicago, Illinois, USA). Adjusted means were estimated using STATA version 12 
(StataCorp LP, College Station, Texas, USA). All statistical tests are two-sided. 
Results 
 
Study Population Characteristics 
Due to frequency matching in the parent nested case-control study, the median age 
at the trial baseline and the prevalence of family history of prostate cancer were similar 
between cases and controls (Table 1). The proportion of non-white men was higher among 
controls due to their oversampling in controls. After adjusting for age, family history, and 
race, the prevalence of smoking and diabetes, and the median BMI and mean prostate 
volume were comparable in cases and controls. The median PSA was higher among 
prostate cancer cases compared to controls both at baseline and at the time of biopsy, 
with the highest concentration observed in men subsequently diagnosed with higher-grade 
prostate cancer (Table 1). As expected given their randomization to the finasteride arm, 
PSA concentration decreased between baseline (before finasteride treatment) and biopsy 
(after 7 years of treatment) most among controls, but also among prostate cancer cases, 
with the exception of higher-grade cases in whom the mean PSA concentration increased 
compared to baseline despite finasteride. Adherence and compliance to finasteride use 
were lower in cases compared to controls, being lowest in men diagnosed with lower-
grade prostate cancer (Table 1). 
 
Prevalence and Extent of Inflammation in Benign Prostate Tissue in Controls 
 The prevalence and extent of inflammation was examined for all patients in the 
finasteride arm (Table 2, All men) as well as for those who were actively taking finasteride 
at the time of biopsy (Table 2, Men on finasteride at time of biopsy) The prevalence of 
inflammation among controls (men without cancer on end of study biopsy) was 92.4% for 
all men in the finasteride arm, and 93.5% in men on finasteride at the time of biopsy (Table 
2). Most of the inflammation present was chronic (313 men, 70.3%); of these men, 131 
(41.9%) had grade 3 chronic inflammation. In contrast, acute inflammation was observed 
only in 34 men (7.6%); of these men, 1 (2.9%) had grade 3 acute inflammation. 
Interestingly, the prevalence and extent of inflammation was higher in the finasteride arm 
(present study) in the control group (without cancer) than in the placebo arm. For example, 
in the controls the number of men with at least one core with inflammation (92.4% on 
finasteride vs. 78.2% not on finasteride; p = <.001), and the mean of mean percentage of 
tissue area with inflammation (16.4% in the finasteride arm vs. 11.5% in the placebo arm; 
p = <.001 ) were both significantly higher in the finasteride arm. 
 
 
Inflammation and Prostate Cancer Risk 
Unlike in the placebo arm (1) no difference in prevalence or extent of inflammation 
was observed between cases and controls overall (Table 2) or by location (intraluminal, 
stromal or epithelial, data not shown) in the finasteride arm. The exception was a lower 
mean percentage of biopsy cores with inflammation, a measure of extent, in lower-grade 
cases compared to controls in the intention-to-treat analysis. However, the difference was 
no longer significant in men on finasteride at the time of biopsy. 
 Overall, unlike in the placebo arm there were no statistically significant associations 
between prevalence or extent of inflammation and the odds of prostate cancer either in the 
intention-to-treat analysis or among men on finasteride (Table 3). An increasing extent of 
inflammation was associated with a decreasing odds of lower-grade disease (P-trend 
0.03), but only in the intention-to-treat analysis.  
  
Inflammation and PSA Concentration 
 Serum PSA concentration at the time of biopsy did not differ by the prevalence or 
extent of inflammation in either cases or controls (Table 4). This is also in contrast to 
findings in the placebo arm (1). The exception was a higher PSA concentration among 
men with at least one biopsy core with inflammation compared to men with no biopsy 
cores with inflammation among those on finasteride at the time of biopsy (P=0.05).  
 Having inflammation in all biopsy cores (versus none) was non-significantly 
inversely associated with prostate cancer in both men with lower (PSA ≤2 ng/ml, OR 0.73, 
95% CI 0.27-2.00) and higher (PSA >2 ng/ml, OR 0.50, 95% CI 0.09-2.88) corrected PSA 
concentration. For higher-grade cancer the pattern of association was different from 
overall; the OR for having inflammation in all biopsy cores was above 1.0 for men with 
PSA >2 ng/ml (OR 1.17, 95% CI 0.17-8.25), but less than 1.0 for men with PSA at ≤2 
ng/ml (OR 0.83, 95% CI 0.21-3.28). 
 
Estimated effect of prostate volume shrinkage on intraprostatic inflammation 
The overall prevalence of intraprostatic inflammation in the PCPT finasteride arm 
was higher compared to the placebo arm (1); the proportion of men with at least one 
biopsy core with inflammation was 92.4% vs. 78.2% in the controls and 91.2% vs. 86.2% 
in prostate cancer cases, respectively. Also, the mean extent of inflammation (mean of the 
mean percentage of tissue area with inflammation) was 5.5% higher in the PCPT 
finasteride arm (16.7%) compared to the placebo arm (11.2%) (1). Because finasteride 
treatment decreases prostate volume, we calculated how much the extent of inflammation 
would increase due to volume reduction if we assume that the absolute amount of 
inflammation-affected tissue would remain constant in the prostate. The median prostate 
volume was 15% lower in the finasteride arm compared to the placebo arm (25.1 vs. 29.5 
cm3, respectively). Therefore, the absolute volume of inflamed tissue in a 30 cm3 prostate 
in a man before finasteride treatment is assumed to be 11.2% x 30 cm3 = 3.36 cm3. If the 
prostate volume decreased by 15%, the new volume would be 0.85 x 30 cm3 = 25.5 cm3.  
Therefore, the extent of the same amount of inflamed tissue in lower volume prostate 
would be 3.36 cm3/25.5 cm3=13.1%, which is 1.9% higher than the assumed original 
extent of 11.2%. Thus, the expected percentage of tissue with inflammation that would be 




In the finasteride arm of the PCPT, we observed a high prevalence and extent of 
inflammation in benign prostate tissue, but did not observe any association between 
intraprostatic inflammation and the risk of total or higher-grade prostate cancer. Further, 
intraprostatic inflammation was not associated with serum PSA concentration in these 
finasteride-treated men.  Previously published results from the PCPT placebo arm 
reported 86% and 78% prevalence of intraprostatic inflammation among prostate cancer 
cases and controls, respectively, with highest prevalence being observed in cases with 
higher-grade disease(1). We show that in the finasteride arm the overall prevalence of 
intraprostatic inflammation was higher, the observed positive association with risk of total 
and higher-grade cancer was fully attenuated, and the observed positive association 
between finasteride-associated inflammation and PSA was missing. 
Finasteride treatment induces both apoptosis and a reduction in cellular volume 
(hormonal atrophy) in the prostate (8), which leads to overall prostate volume reduction. 
Androgens and androgen deprivation therapy influence the immune system both 
systemically (9) and locally (10). Local prostate effects are characterized by an increased 
number of macrophages, dendritic cells, and T-cells in the tissue (10). Androgen ablation 
makes normally tolerant T-cells recognize prostate antigens and proliferate in response to 
them (4). Although we did not assess specific types of inflammatory cells present, the 
markedly elevated prevalence of intraprostatic inflammation in the finasteride arm relative 
to the placebo arm suggests that similar effects result also from local androgen inhibition in 
the prostate in response to 5α-reductase inhibition. This is supported by an even higher 
prevalence of inflammation in men still on finasteride at the time of biopsy. 
To determine whether the hypothesis of absolute or proportional increase in 
inflammation is more likely, we considered the possible effect of prostate volume reduction 
during finasteride treatment on extent of inflammation. This analysis indicated that while 
some of the increase in inflammatory cells could be the result of gland shrinkage, the 
estimated increase in inflammation extent due to overall volume decrease by finasteride 
does not entirely explain the greater extent of intraprostatic inflammation in finasteride-
treated men compared to the placebo arm. Instead, our findings suggest that finasteride 
treatment induces intraprostatic inflammation as has been previously reported for other 
types of androgen deprivation (9,10). 
Unlike in the previous study in the PCPT placebo arm (1), we did not observe an 
association between intraprostatic inflammation and risk of prostate cancer overall or 
higher-grade disease in the finasteride arm. This may be because the high prevalence of 
inflammation in finasteride-treated men makes comparisons underpowered given our 
sample size, or because chronic finasteride-associated inflammation  is not a prostate 
cancer risk factor as it is in placebo-treated men. The latter notion is supported by the lack 
of an association between finasteride-associated inflammation and PSA level; 
inflammation induced by finasteride treatment may not cause such damage to prostate 
epithelial cells that would allow PSA to leak into circulation, or finasteride treatment may 
attenuate the cytotoxic effects of inflammation. The immune cells induced to infiltrate the 
prostate during finasteride therapy may not be pro-carcinogenic; in fact they may be anti-
tumorigenic (10). Inflammation observed in the placebo arm may also reflect more long-
standing and etiologically relevant inflammation, whereas finasteride-induced inflammation 
could have started only after PCPT randomization, at maximum seven years earlier. 
Further research will be needed to clarify which of these speculations, if any, is 
explanatory. 
The lack of an association between finasteride-associated inflammation and PSA  
also has implications for the accuracy of PSA as a tumor marker. If benign causes of PSA 
elevation, such as intraprostatic inflammation, are removed by finasteride treatment, the 
performance of PSA would be enhanced as a prostate cancer tumor marker. 
Concordantly, an earlier PCPT analysis reported improved sensitivity of PSA to detect 
prostate cancer during finasteride treatment (11). In the current analysis, PSA was 
decreased at prostate biopsy as compared with the baseline level obtained before starting 
finasteride, except in those later diagnosed with higher-grade cancer. This observation 
suggests that PSA elevation is more specific to higher-grade prostate cancer during 
finasteride therapy. 
We observed a possible inverse association between extent of finasteride-
associated inflammation and risk of lower-grade prostate cancer. This finding was not 
explained by differing likelihood of a prostate biopsy as the association was also inverse 
even in men with a low corrected PSA (≤2 ng/ml). We also observed that lower-grade 
cases had a lower prevalence and extent of inflammation than controls; these differences 
were attenuated when restricting to men on finasteride at the time of biopsy.  
Our study has several unique strengths. Prostate cancer screening and diagnosis 
were standardized by the PCPT study protocol, and tumor diagnosis and Gleason sum 
were confirmed by central pathological review. The pathologist who assessed 
inflammation in all biopsy cores was trained to evaluate inflammation by a consensus-
developed system (7), and was fully blinded to case-control status and treatment arm, 
which reduces the potential for observation bias. We also had the unique opportunity to 
evaluate the association between intraprostatic inflammation and prostate cancer risk in 
men with very low PSA, allowing evaluation of biological effects in the prostate without the 
possible detection bias due to inflammation affecting PSA level and likelihood for prostate 
biopsy.  
Our study also has some limitations. Although PCPT was a prospective randomized 
trial, our current nested case-control study was a retrospective analysis. Inflammation in 
prostate cancer tissue was evaluated only at one time-point (time of biopsy) and we could 
not evaluate time trends in intraprostatic inflammation during finasteride usage. Further, 
we could not determine whether inflammation in benign tissues of cancer cases was due 
to the tumor or vice versa. Prostate biopsies are taken mainly from the peripheral zone of 
the prostate where malignancy usually occurs. We could not determine whether 
inflammation in central areas (e.g. the transition zone) of the prostate is associated with 
prostate cancer risk. Participants of the PCPT trial were selected to be men with low risk of 
prostate cancer at baseline, and were screened yearly for the entire duration of the trial. 
Thus, we could not evaluate associations between inflammation and metastatic prostate 
cancer at diagnosis or prostate cancer death. Finally, due to low number of non-white men 
we could not evaluate the association between intraprostatic inflammation and prostate 
cancer separately by race. 
In conclusion, we found that men using finasteride have an increased prevalence 
and extent of intraprostatic inflammation compared to men not using finasteride. 
Nevertheless, finasteride-associated inflammation was not associated with risk of higher-
grade prostate cancer or PSA in contrast to findings in the PCPT placebo arm. Finasteride 
may improve the accuracy of PSA as a tumor marker, if it does indeed minimize PSA 
elevation due to inflammation. Future studies will need to address whether increased 
inflammation in finasteride-treated men is due to sustained cell death and hormonal 
atrophy in prostate tissue, and whether intraprostatic inflammation is associated with 
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Table 1. Characteristics* of prostate cancer cases and controls**, finasteride arm, Prostate Cancer Prevention Trial 
 Controls Prostate cancer cases 
  Total Lower grade 




N 248 197 97 100 
Mean age at baseline (years) 64 64 64 65 
Mean age at biopsy (years) 74 71 71 72 
Non-white; n (%) 60 (24.2) 21 (10.7)# 10 (10.3)# 11 (11.0)# 
Family history; n (%) 53 (21.4) 41 (20.8) 22 (22.7) 19 (19.0)
Cigarette smoking history; n (%)     
Current 16 (6.5) 11 (5.6) 3 (3.1) 8 (8.0) 
Former 144 (58.1) 120 (60.9) 57 (58.8) 63 (63.0) 
Never 88 (35.5) 66 (33.5) 37 (38.1) 29 (29.0) 
Mean pack-years smoked, current and former smokers 13.8 14.4 14.4 14.6 
Mean body mass index (kg/m2) 27.9 27.5 27.3 27.7 
History of diabetes; n (%) 16 (6.5) 10 (5.1) 4 (4.1) 6 (6.0) 
Mean prostate volume (cc) 27.3 26.2 26.1 26.4 
Mean PSA***     
Concentration at baseline (ng/mL) 1.10 1.50# 1.43# 1.56# 
Concentration at biopsy (ng/mL) 0.54 1.28# 1.28# 1.49# 
Mean annual change in PSA (ng/mL/year) -0.62 -0.07# -0.30# 0.16# 
Adherence to finasteride use; n (%) 231 (93.1) 170 (86.3)# 82 (84.5)# 88 (88.0) 
Mean compliance with finasteride treatment (%) 91.8 85.5 82.5 88.4 
*For all characteristics except baseline age, family history of prostate cancer, and race, values were calculated by generalized linear models (linear for 
adjusted proportions and means and logistic for P-values) adjusting for baseline age, family history, and race. 
**In the parent nested case-control study, cases and controls were frequency matched on baseline age and family history. All non-white controls were 
sampled. For this tissue-based study, cases were sampled from the finasteride arm of the trial so that half were higher grade (Gleason sum ≥7) and half were 
lower grade (Gleason sum <7), and of these half were detected on a biopsy performed for an elevated PSA or an abnormal digital-rectal examination (for-
cause biopsy) and half were detected on a biopsy performed at the end of the trial per trial protocol (end-of-study biopsy). Controls were sampled from men 
who were negative for prostate cancer on the biopsy performed at the end of the trial per protocol. 
*** Uncorrected PSA concentrations (see Methods) 
#P<0.05 compared with controls. 
 
  
Table 2. Prevalence and extent* of inflammation assessed in benign prostate tissue from biopsy cores in prostate cancer cases overall and by grade and 
controls**, finasteride arm of the Prostate Cancer Prevention Trial 
 
 All men Men on finasteride at the time of biopsy 
 Controls  Prostate cancer 
cases 
Controls Prostate cancer cases 









N 248 197 97 100 231 170 82 88 
     
93.5 92.9 93.9 92.0 At least one biopsy core with inflammation 
(%)*** 
92.4***** 91.6***** 90.2 92.7 
Mean of the percentage of biopsy cores with 
inflammation*** 71.0 67.7 62.1# 73.0 72.0 70.3 66.7 73.7 
Mean of the mean percentage of tissue area 
with inflammation****     
    
Overall 16.4 17.0 14.6 19.0 16.8 17.8 15.3 20.1 
In men with at least one biopsy core with 
inflammation 17.7 18.5 16.3 20.4 18.0 19.1 16.3 21.8 
         
 
*From generalized linear models (linear for adjusted proportions and means, logistic for P-values) adjusting for baseline age, family history of prostate cancer, 
and race. 
** In the parent nested case-control study, cases and controls were frequency matched on baseline age and family history of prostate cancer. All non-white 
controls were sampled. For this tissue-based study, cases were sampled from the finasteride arm of the trial so that half were higher grade (Gleason sum ≥7) 
and half were lower grade (Gleason sum <7), and of these half were detected on a biopsy performed for an elevated PSA or an abnormal digital-rectal 
examination (for-cause biopsy) and half were detected on a biopsy performed at the end of the trial per trial protocol (end-of-study biopsy). Controls were 
sampled from men who were negative for prostate cancer on the biopsy performed at the end of the trial per protocol. 
***For each man, the denominator is total number of biopsy cores evaluated. 
****For each man, the denominator is total benign tissue area across all biopsy cores evaluated on each of the man’s slides. 
***** The prevalences in the PCPT placebo arm were 78.2% in controls and 86.2% in cases (1). 





Table 3. Association* between inflammation assessed in benign prostate tissue from biopsy cores and prostate cancer risk, overall and by 
grade, finasteride arm, Prostate Cancer Prevention Trial 
 
 Prostate cancer cases, all Prostate cancer cases, men on finasteride at the time of 
biopsy 
 Total Lower grade Higher grade Total Lower grade Higher grade 
N 197 97 100 170 82 88
At least one biopsy core with inflammation      
OR 0.90 0.75 1.07 0.93 1.03 0.79 
95% CI 0.44-1.84 0.32-1.75 0.43-2.69 0.42-2.08 0.35-3.02 0.31-2.06 
Extent of biopsy cores with inflammation      
Zero cores       
OR 1.00 1.00 1.00 1.00 1.00 1.00 
95% CI Reference Reference Reference Reference Reference Reference 
Some cores       
OR 1.00 0.97 1.00 1.00 1.30 0.72 
95% CI 0.48-2.09 0.40-2.32 0.38-2.58 0.44-2.31 0.43-3.91 0.27-1.93 
All cores       
OR 0.80 0.52 1.16 0.86 0.76 0.87 
95% CI 0.38-1.68 0.21-1.30 0.45-3.00 0.37-1.98 0.25-2.34 0.33-2.34 
P-trend 0.68 0.03 0.57 0.49 0.13 0.77 
 
*From a logistic regression model adjusting for the matching factors (baseline age and family history of prostate cancer) and for oversampling of non-white 
controls. In the parent nested case-control study, cases and controls were frequency matched on baseline age and family history of prostate cancer. All non-
white controls were sampled. For this tissue-based study, cases were sampled from the finasteride arm of the trial so that half were higher grade (Gleason 
sum ≥7) and half were lower grade (Gleason sum <7), and of these half were detected on a biopsy performed for an elevated PSA or an abnormal digital-
rectal examination (for-cause biopsy) and half were detected on a biopsy performed at the end of the trial per trial protocol (end-of-study biopsy). Controls 
were sampled from men who were negative for prostate cancer on the biopsy performed at the end of the trial per protocol. 
 
  
Table 4. Mean serum PSA concentration at biopsy* by prevalence and extent of inflammation assessed in benign prostate tissue from biopsy 
cores in the controls and prostate cancer cases, finasteride arm, Prostate Cancer Prevention Trial 
 
 All men Men on finasteride at the time of biopsy 
 


















No Yes Some All No Yes Some All
CONTROLS   
Total (N) 19 229  115 114  15 216  107 109  
Mean PSA at biopsy 
(ng/ml)*** 0.56 0.60 0.51 0.58 0.61 0.34 0.38 0.55 0.05 0.55 0.55 0.22 
             
Without indication for 
biopsy (N) 16 217  110 107  13 206  104 102  
Mean PSA at biopsy 
(ng/ml)*** 0.59 0.58 0.74 0.58 0.58 0.53 0.39 0.54 0.06 0.55 0.52 0.48 
             
CASES             
Total (N) 16 181  99 82  12 158  83 75  
Mean PSA at biopsy 
(ng/ml) 1.33 1.54 0.58 1.61 1.46 0.74 1.10 1.40 0.41 1.50 1.28 0.60 
             
Detected on a for-
cause biopsy (N) 8 90  48 42  6 82  43 39  
Mean PSA at biopsy 
(ng/ml)*** 1.67 2.12 0.43 2.29 1.91 0.57 1.23 1.88 0.29 2.14 1.58 0.34 
             
Detected on an end-of-
study biopsy (N)**** 8 91  51 40  6 76  40 36  
Mean PSA at biopsy 
(ng/ml)*** 0.99 0.97 0.92 0.96 0.99 0.90 0.98 0.88 0.63 0.81 0.95 0.55 
*From linear regression models adjusting for age at baseline.  
**Across no (zero), some, all biopsy cores with inflammation. Reference is men with “No” (zero) biopsy cores with inflammation. 
*** Uncorrected PSA concentrations (see Methods) 
****Without an indication for biopsy.  
 
